SITEMAP
-
Science
- Cutting Edge Science
- Inspiration and Innovation
- Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
-
Asthma
-
Cutting Edge Science
- 2021
- Innovation
- 2022
-
2023
-
2024
- Severe Asthma Biomarker's
- The Vital Role of Lung Function in Asthma Care
- Sever Asthmatic patients with OCS
- Asthma Clinical Remission: The Benchmarks for Eliminating Airway Inflammation and Symptoms
- Fractional exhaled nitric oxide (Feno)
-
Airway Hyperresponsiveness
in Asthma - ON-TREATMENT ASTHMA REMISSION: MOVING BEYOND CONTROL
-
2025
- FeNO Is a Clinically Useful Biomarker of Type 2 Inflammation in Pediatric Patients With Asthma
-
Mucus Plugging Is a Key Component of Remodeling
in Asthma, Leading to Fixed Airway Obstruction - VESTIGE study
- VESTIGE Trial Results: Dupilumab in Type 2 Asthma
- Pediatric Management
- Assessing Pediatric Lung Function
- Understanding Airway Obstruction: The Role of Mucus Plugging in Asthmatic Disease
- The Role of Mucus Plugging in Asthma and Its Clinical Burden
-
2026
- IL-4, IL-13, AND IL-5 ARE DRIVERS OF SYSTEMIC TYPE 2 INFLAMMATION
- IL-4/IL-13 Dual Cytokine Signaling in Severe Asthma: Mechanistic Insights by Prof. Kenneth Chapman
- LIBERTY ASTHMA QUEST Trial: Dupilumab Efficacy in Eosinophilic (≥500 cells/µL) and Allergic Asthma Subgroups
- LIBERTY ASTHMA TRAVERSE Trial: Long-Term Safety and Efficacy of Dupilumab in Moderate-to-Severe Asthma
- Dupilumab improves clinical outcomes in patients with severe asthma compared to other biologics
- LIBERTY ASTHMA QUEST Trial: Dupilumab Evidence Summary in Moderate-to-Severe Uncontrolled Asthma
- LIBERTY ASTHMA QUEST Trial: Dupilumab Efficacy in Type 2 Asthma Patients on High-Dose ICS
-
Cutting Edge Science
-
Atopic Dermatitis
-
Cutting Edge Science
-
2021
- 2024
-
2024
- The role of Epithelial Barrier Components in AD, insights and implications
- Long Term Impact of AD and the Potential benefits of early intervention
- IL4 and IL13 important role in Chronic Itch
- The Cumulative Disease Burden of AD in Adult Patients
- Type 2 Inflammation in Skin Tissue: Exploring Shared and Distinct Pathways in Prurigo Nodularis and Atopic Dermatitis
- AD and PN: Diagnosis and Impact on Quality of Life
- Atopic Dermatitis in Children: High Burden and Limited Treatment Options
- Association of Younger Age of Onset with Persistence of Atopic Dermatitis
- Disease Modification Concepts in Atopic Dermatitis
- What Could Remission Mean in Atopic Dermatitis
- Can Early Therapeutic Intervention Shape Disease Course in Pediatric AD
- Impact of Advanced Systemic Therapies on Disease Control in AD
- Can Early Intervention Shape the Course of Atopic Dermatitis
- Factors Associated with Development of Atopic Comorbidities in AD
- Improving Quality of Life in Patients with Uncontrolled Atopic Dermatitis (AD): Tools for Timely Identification and Treatment
- Unseen Burdens: How Cumulative Life Course Impairment (CLCI) Affects Patients with Moderate-to-Severe Atopic Dermatitis (AD)
- The Hidden Impact of Cumulative Life Course Impairment (CLCI) in Dermatology: An Overview
- Understanding Cumulative Disease Burden in Uncontrolled AD
- Early Intervention and Disease Modification in Atopic Dermatitis
- Charting New Course: The Frontier of Early Intervention and Disease Modification in AD
- Innovation
-
2021
-
Cutting Edge Science
- Bullous Pemphigoid
- Cardiovascular
- Chronic Obstructive Pulmonary Disease
-
Diabetes
-
Cutting Edge Science
-
2021
-
Innovation
- 2022
- ATTD 2021: Patients’ profiles for digital tools
- ATTD 2021: Technology Supporting Initiation, Titration, and Intensification
- The InRange Study
- Is Premixed Insulin an Effective Treatment for Type 2 Diabetes Uncontrolled by OADs?
- Summary of SAGE study on Adults with T1DM
- The SoliRam observational study
- Edition Junior Study - Helping patients with type 1 diabetes (T1D) to find better treatment options
- Expert consensus statement on management of older adults with type 2 diabetes (T2D)
- SoliMix Study Results Summary
- Time-In-Range (TIR): How to interpret it and how it is associated with outcomes
- Challenges associated with commonly-used insulin advancement options
- EVOLUTION: RWE from Saudi Arabia
- Advancing Therapy with iGlarLixi: Differentiation from other complex regimens
- Glargine 300 use in people with type 2 diabetes who fast during Ramadan
-
2022
- Selecting a CGM device
- Limitations with the use of BGM
- Commercially available CGM systems
- Case 2 T1D
- Case 1 T2D
- Benefits of using CGM vs BGM
- A narrative review for clinicians on insulin management for Type 2 Diabetes during Ramadan
- Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.
- Closed-loop insulin delivery during exercise in people with T1D
- Diabetes management during Ramadan
- Management of athletes and active people with diabetes - The American Medical Society for Sports Medicine (AMSSM) scientific statement
- Post-exercise hypoglycemia in relation to medication regimen among adults with type 2 diabetes
- iGlarLixi Enables Safe Ramadan Fasting for Most T2D Patients
- Recommendations on treatment simplification of complex insulin regimens to improve clinical outcomes in patients with T2DM
-
Single Injectable Treatment May Not Be Enough To Get T2dm Patient To Glycemic Goal
- 2023
-
2024
- Inside Diabetes: ATTD Edition | Type 1 Diabetes
- Need to redefine the treatment paradigm Post OAD
- Unveiling Significance of Time in Range: Value as key Glycemic Biomarker
- The Evolving Role of Treatment and Technology in Diabetes Care
- Time-in-Range: A Key Determinant of Quality of Life
- SoliD: Redefine Treatment Paradigm Post-OAD
- Groundbreaking SoliD Study: Comparative Efficacy of iGlarLixi and IDegAsp
- The ATOS Study: Real-World Study on Effectiveness of Insulin Glargine U300 in the Gulf Region.
- Why to screen for Autoimmune T1D
- How to screen for Autoimmune T1D
- The burden of Autoimmune T1D
- Understanding Autoimmune T1D disease & Different Stages
-
2025
- Consensus Guidance for Monitoring Children with Islet Autoantibody-Positive Pre-Stage 3 Autoimmune Type 1 Diabetes (T1D)
- New Horizon in management of high-risk patients with Diabetes
- Effective Treatment Simplification
- Stages of Type 1 Diabetes and DKA Impact
- Early Detection and Intervention
- Recommendation for Screening
- Prevalence of Type 1 Diabetes and Daily Life Impact
-
2021
-
Cutting Edge Science
- Eosinophilic Esophagitis
- Immune Thrombocytopenia ITP
- Multiple Myeloma
-
Multiple Sclerosis
-
Cutting Edge Science
-
2022
- A promising biomarker in MS: Neurofilament light chain
- How old is your brain?
- Exercise as ”medicine” in the treatment of MS
- MS Updates
- Cognitive training – A curse or a blessing?
- Thalamic atrophy as a new biomarker of MS? The predictive value and how to use in clinical practice
- Measuring brain atrophy. What can be done and where are we heading?
- Cognitive decline – The invisible burden of MS?
- Falling chronically ill – How do I cope and move forward?
- The importance of deep grey matter in MS
- The reason for MS – beyond focal inflammation
- Why has our brain suddenly become of interest?
- Innovation
-
2023
- 2024
- 2025
-
2026
- Understanding PIRA in MS: An Overview with Dr. Barry Singer
- Understanding Kaplan–Meier Curves in MS: An Overview with Dr. Barry Singer
- Understanding 6‑Month CDP in MS: An Overview with Dr. Barry Singer
- MS Pulse Reels - MS Monitoring in Practice | Turning Tracking into Action
- MS Pulse Reels - How to Track MS | Acknowledge, Assess, Advocate
- MS Pulse Reels - See the Bigger Picture: Why Tracking Matters
-
2022
-
Smoldering Neuroinflammation
-
MS Pulse Reels
-
Cutting Edge Science
-
Nasal Polyps
-
Cutting Edge Science
-
2021
- 2022
-
2023
- What does patient empowerment mean for your treatment plan?
- Type 2 Inflammation Is The Underlying Cause Of Crswnp In 80% Of Patients.
- Hear From An Expert On Would You Consider A Biologic For A Surgery-Naïve Patient With Crs With Nasal Polyps?
- “Smell—we call it the Cinderella of the senses"
- What can biologic treatment do for patients with CRS with nasal polyps?
- "It really has changed the way I manage our patients"
- Hear From An Expert On How Does Dupixent Target Underlying Type 2 Inflammation?
- You can imagine more than 90% of CRSwNP patients losses their ability's of smell
- How does Dupixent help recover smell?
- NPS improvement with Dupixent over time
- Hear From An Expert On Identify Patients Who Are Appropriate Candidates For Biologic Treatment
- 2024
-
2025
- IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP
- Loss of Smell Is a Key Symptom in CRSwNP
- Loss of Smell Improvement in Patients With CRSwNP
- EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP
- CRSwNP EVEREST
-
2021
-
Cutting Edge Science
- Neurological Disorders
-
Prurigo Nodularis
-
Cutting Edge Science
-
2022
- Type 2 Inflammation may play a role in Prurigo Nodularis Pathophysiology1
- Mechanism of Prurigo Nodularis Disease
- Prurigo Nodularis is a distinct, Chronic, Neural and Immune- Mediated skin disease characterized by intense itch and Nodular Lesions¹
- There is significant unmet need in the management of PN¹
- 2024
-
2022
-
Cutting Edge Science
-
Rare Diseases
-
Cutting Edge Science
-
Innovation
- 2022
- Bone Monitoring Guidelines in Gaucher Disease Video
- Diagnostic Algorithm for Gaucher Disease in Adult
- Diagnostic Algorithm for Gaucher Disease in Pediatric
- Pompe video
- Lysosomal Storage Diseases from Neurology Perspective
- Professor Fatma Al-Jasmi video on ASMD
- Professor Moeen Al Sayed video on ASMD
- Professor Tawfeq Ben Omran video on ASMD
- Their Stories shaped them like Pearls
- Diagnostic challenges of LOPD
- Early diagnosis and management of IOPD
- LSDs overview
- How is LSDs prevalence & epidemiology different in our region?
- Multidisciplinary approaches in Rare Disease Patient management in KSA
- What are the new diagnostics modalities used to expedite Rare Disease patients identification?
- What are Lysosomal Storage disorders?
- Fabry Disease from Cardiology Perspective
- When shall we think of a rare disease from Neurological perspective
- Extraordinary measures: what are the benefits to have such movies talking about Rare Diseases?
- IOPD Challenges
- Have you considered Pompe Disease?
- Social stigma
- The role and importance of Patients Associations and Scientific societies ; UAE experience
- The Stigma of Rare Diseases
- The role and importance of Patients Associations and Scientific societies ; Oman Experience
- Multidisciplinary approaches in Rare Disease Patient management
- What is the role of Artificial Intelligence in accelerating patient's diagnosis?
- Gaucher disease awareness month video
- How To Diagnose LSDs?
- Better care for Fabry
- 2022
-
2023
- Differential Diagnosis Of Late Onset Pompe Disease (LOPD) and Myotonic Dystrophy Type 1 Through Abdominal Ultrasonography
- Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease for orthopedists
- Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease (LOPD)
- Experts recommendations on Late Onset Pompe Disease (LOPD) differential diagnosis from GCC
- Fabry
- Expert Group Consensus From the Arabian Peninsula On the Diagnosis of Lopd
- Expert Group Consensus From the Arabian Peninsula On the Diagnosis of Lopd
- Pompe
- Prevalence Of LOPD In Patients With Undifferentiated Proximal Myopathy And Undiagnosed Muscle Biopsy
- An overview of Lysosomal Storage Disorders & Sanofi`s Commitment to the Development and Provision of Treatments
- Gaucher
-
2024
- ROLE OF ECG IN DIFFERENTIAL DIAGNOSIS OF ANDERSON–FABRY DISEASE WITH HCM
- BIOCHEMICAL DIAGNOSTIC STRATEGY IN FEMALES SUSPECTED OF FABRY DISEASE
- DIAGNOSING FABRY DISEASE IN CLINICAL PRACTICE
- Consensus Guidelines for the Clinical Management of ASMD
- Pompe Care Podcast Series
- Navigating the Pompe Disease Journey
- Impact of symptoms and risk of ASMD on patients and caregivers
- Differential diagnostics for ASMD in patients suspected to have GD
- What Are the Signs and Symptoms of ASMD?
- ASMD
- Legacy Video for Rare Disease Academy
- Uncover ASMD and GAUCHER
-
2025
- Every Moment Matters: Navigating Diagnosis of Fabry Disease
- Safety and efficacy of Avalglucosidase Alfa versus Alglucosidase Alfa in patints with Late-Onset Pompe Disease (COMET): a phase 3, randomized, multicentral study results
- Long-term Safety and Efficacy of Avalglucosidase Alfa IN Patients with Late-Onset Pompe Disease (NEO-EXT)
- Understanding Gaucher Disease Type 3
-
2026
- Gaucher Mechanism of Disease
- Gaucher Neurology Diagnosis Support
- Gaucher Haematology Diagnosis Support
- Gaucher Biochemistry Diagnosis Support
- Fabry Disease in Cardiology Practice: From Red Flags to Diagnosis
- Tolerability of Accelerated Agalsidase Beta Infusions in Fabry Disease: The SHORTEN Study Analysis
- From Registry to Reality: Reduced Stroke Incidence with Agalsidase Beta in Fabry Disease
- When Weakness Tells a Bigger Story
- The Many Faces of Limb-Girdle Weakness
- When the Heart, Kidneys, and Nerves Intersect
- When Hematological Signs Lead the Diagnosis
- The Enlarged Spleen Mystery
- Renal Outcomes After Switching to Agalsidase Beta: A Single-Center Analysis
- Structured Monitoring for Early Detection of Fabry Progression
- Pompe Care Podcast Series 3
- What factors influence your decision to switch a patient from alglucosidase alfa to avalglucosidase alfa?
- How has avalglucosidase alfa impacted the treatment paradigm for both infantile-onset and late-onset Pompe disease in your experience?
- Have you observed any significant differences in treatment outcomes between these two therapies in your local practice?
- What challenges do clinicians face in monitoring in disease progrission and response to therapy?
- Pompe Care Podcast Series 2
- What has been your experience with switching patients from alglucosidase alfa to avalglucosidase alfa?
- What makes avalglucosidase alfa different from alglucosidase alfa in terms of clinical efficacy and patient outcomes?
- How can you see changing the lives of patient starting taking Nexviazyme and if you can share from your experience couple of patient stories that realy impacted positively from staring the treatment for Pompe disease?
- Thank You!
-
Innovation
- Gaucher
- Fabry
- Pompe
- ASMD
-
Cutting Edge Science
-
Vaccines
- Influenza
-
RSV
-
Cutting Edge Science
- 2023
- 2024
-
2025
- RSV Burden in Jazan
- Beyond High-Risk: Expanding RSV Protection for Newborns and Infants
- New horizon of RSV lower respiratory tract disease LRTD in infants: Reflection on two seasons of prevention
- Nirsevimab RWD Metanalysis
- Kuwait taking the lead in RSV protection for all infants in the Middle east
- Ensuring overall RSV prevention in every individual Dr. Alia Podcast
- Nirsevimab FAQs
- Healthcare Utilization and Economic Burden of RSV Infections Among Children Under 5 Years in Saudi Arabia: A MNGHA Facilities Analysis
- Evidence on Nirsevimab: Sustained Impact Across Two RSV Seasons
-
2026
- RWE data on Nirsevimab and RSV preF vaccine
- Expanding RSV Protection in Kuwait: New National Directives for Monoclonal Antibody Use
- Real-World Effectiveness of Nirsevimab: Evidence from the NIRSE-GAL Study
- RSV Prevention Guidelines in UAE
- An overview of the latest Saudi evidence presented at ESPID 2026.
- An overview of the latest Saudi evidence presented at ESPID 2026.
- Healthcare Utilization and Economic Burden of Pediatric Lower Respiratory Tract Infections Across Five Tertiary Hospitals in Saudi Arabia
-
Cutting Edge Science
- Mass Gathering
- Rhinology
- Legal Notice
- Cookie Policy
- Privacy Policy
- Search
- My Account
- Incomplete Profile Notice
- Incomplete Profile
- Patient Support
- Qatar Contact Details
- Events Calendar
-
Products
- Adacel®
- Aubagio®
- Cablivi®
- Cerezyme®
- Clexane®
-
Dupixent®
- Prurigo Nodularis
- Atopic Dermatitis
- Dupixent® COPD
- Dupixent Asthma
- Nasal Polyps
- A Message to You from Dr. Ayman AlNaeem
- How Dupixent Changed Dr. Ayman AlNaeem’s Approach in AD Treatment
- Dr. Ayman Alnaeem’s Very First Dupixent Patient Experience
- The Burden of AD through Dr. Ayman Alnaeem’s Expertise/eyes
- The Burden of AD by Dr. Paula Nelson
- Dr. Paula Nelson’s Very First Dupixent Patient Experience
- Dr. Paula’s insights on treating AD patients with Dupixent
- Fabrazyme®
- Lemtrada®
- Myozyme®
- Nexviazyme
- Praluent®
- Solian®
- Soliqua®
-
Toujeo®
- Toujeo for a Peaceful Ramadan
- Wall of Evidence
- Toujeo T1DM
- Toujeo T2DM
- How to Start
- Toujeo Innovation
- Time in Range
- Second generation basal insulin in advancing T2D therapy
- Timely insulin initiation to limit disease progression
- Meet the Expert
-
Always On
- How to Start People with Diabetes to Toujeo
- Bridging the Glycemic Gap- Timely Transition from OADs to Toujeo
- Evolving Basal Insulin Therapy- From 1st Gen to 2nd Gen
- The Kidney-Diabetes Connection- Clinical Use of Toujeo in Dual Diagnosis
- Toujeo vs Degludec- Clinical Insights from the BRIGHT study for Insulin selection
- Toujeo and GLP1s- Optimising Glycemic Control in Uncontrolled T2D
- New Findings on Toujeo® for T2D Management Following Dual GIP-GLP-1 RA Therapy
- Xatral®
- Xenpozyme®
- Events
- Sitemap
- Registration